logo
Plus   Neg
Share
Email

Myriad, AstraZeneca Expand Collaboration To Include MyChoice HRD Plus Diagnostic

Myriad Genetics, Inc. (MYGN) announced that AstraZeneca will use the company's myChoice HRD Plus in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab). Myriad will use its myChoice HRD Plus test to evaluate patients enrolled in an ongoing Phase III trial. Under the collaboration, the companies will use the myChoice HRD Plus test to identify cases with homologous recombination deficiencies.

Myriad's myChoice HRD Plus is a homologous recombination deficiency test to detect when a tumor has lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Monsanto on Thursday pleaded guilty to illegally using a banned pesticide known as Penncap-M on research crops at one of its facilities on the Hawaiian island of Maui. The agro-chemicals company will pay $10 million for charges that it unlawfully stored the banned pesticide, which had to be managed as an acute hazardous waste. The banned pesticide is specifically methyl parathion. Anti-aging skin care products, beauty serum ingredients and essential oils provider Resurrectionbeauty issued a recall for about 270 units of wintergreen essential oil due to risk of poisoning for young children if they swallow it. However, the company has not received reports of any incidents or injuries so far. The product contains the substance methyl salicylate. Microsoft has delayed the worldwide launch of its Surface Earbuds till Spring 2020. The $249 wireless earbuds were originally expected to launch this year. The delay is a setback in Microsoft's attempt to compete with Apple's latest earbuds, AirPods Pro, which has a new design and features active noise cancellation.
RELATED NEWS
Follow RTT
>